



BDAE
JAN 10 2005

Patent Application
Attorney Docket No. 31355 US

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents, Alexandria, VA 22313-1450 on this 10 day of January, 2005.

By _____

(Signature of person mailing)

Andrea E-Dorigo

Reg. No. 47,532

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Martino et al. :

APPLICATION NO.: 10/072,368

: Examiner: Hui

FILING DATE: 02/07/2002

: Group Art Unit: 1617

TITLE: RAPID-ONSET MEDICAMENT FOR
TREATMENT OF SEXUAL
DYSFUNCTION

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

PETITION FOR REVIVAL OF UNINTENTIONALLY ABANDONED
APPLICATION UNDER 37 C.F.R. §1.137(b)

The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Official Action of February 12 2004 plus any extensions of time actually obtained.

Applicants hereby petition for revival of this application. A grantable petition requires the following items:

- (1) Petition fee;
- (2) Reply; and
- (3) Statement that the entire delay was unintentional.

Patent Application
Attorney Docket No.31355 US

The petition fee is the fee for other than a small entity under 37 CFR § 1.17(m). The Commissioner is hereby authorized to charge this fee to Deposit Account No. 16-1445.

A response to the Official Action of February 12 2004 is enclosed herewith.

Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.

Finally, applicants hereby state that the entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR § 1.137(b) was unintentional.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Date: January 7, 2005

Andrea Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Pfizer Inc
Patent Department
150 East 42nd Street – 5th Floor
New York, NY 10017-5755
(212) 733-1898